Can you take topiramate with Wegovy at the same time?

Why does the topiramate-and-Wegovy question come up at all?

Topiramate is an anticonvulsant licensed in the UK primarily for epilepsy and migraine prevention. It also has a well-documented effect on body weight: many people taking it notice reduced appetite and lose weight as a side effect, which is why it sometimes appears in conversations about weight management even though it is not licensed for that purpose in the UK. Wegovy (semaglutide 2.4mg) is, by contrast, specifically licensed for weight management in adults with a BMI of 30 or above, or 27 with a weight-related health condition, used alongside dietary changes and increased activity.

The overlap matters because a prescriber looking at someone on topiramate who then asks about Wegovy is effectively looking at two appetite-modifying agents at once. That is not an automatic barrier, but it does change the assessment. The NHS semaglutide medicines page lists interactions and side effects to be discussed with a clinician before starting treatment, and topiramate's profile sits squarely in that conversation.

Questions about the wider semaglutide interaction picture are answered in detail on the medicines to avoid with semaglutide page.

What are the specific risks of taking both together?

Three areas tend to concern prescribers most. First, the appetite-suppression overlap. Topiramate reduces food intake through central mechanisms; semaglutide slows gastric emptying and acts on hypothalamic appetite pathways. Running both simultaneously can reduce calorie intake more sharply than expected, and inadequate nutrition (particularly protein) is a real consequence of under-eating on GLP-1 therapy regardless of whether topiramate is involved.

Second, dehydration. Topiramate can reduce the body's ability to sweat normally and may affect kidney stone risk. Wegovy commonly causes nausea, vomiting and diarrhoea, particularly at the start of treatment and after dose increases. When GI side effects reduce fluid intake and topiramate is already nudging the system toward fluid imbalance, dehydration can develop faster than either medicine would produce alone. That is the kind of compounding risk a prescriber is specifically weighing — it is also why the full list of medicines that interact with Wegovy includes anything that impairs hydration or kidney function.

Third, cognitive side effects. Topiramate is associated with word-finding difficulties and cognitive slowing in some patients. There is no established pharmacokinetic interaction with semaglutide, but if someone is already experiencing cognitive effects from topiramate, that should be flagged in any new prescription assessment.

The MHRA's January 2026 Drug Safety Update on GLP-1 medicines is worth mentioning here: severe, persistent stomach pain that spreads to the back should always prompt urgent medical attention, as it may indicate acute pancreatitis, a risk that exists with semaglutide and which a prescriber will factor in when reviewing a complex medication list. You can report any suspected side effects at the MHRA's Yellow Card scheme.

Should you stop one medicine before starting the other?

This is really a question for the prescriber who holds both prescriptions. There is no universal rule that topiramate must be discontinued before Wegovy can be started, or vice versa. What matters is the reason topiramate is prescribed in the first place. If it is controlling epilepsy, stopping or reducing it carries serious and immediate risks that would outweigh almost any benefit from simplifying a medicines list. If the prescriber who put it on repeat is a neurologist, they need to be part of the conversation before anything changes.

If topiramate is being used for migraine prevention and weight management has since become the clinical priority, a specialist review might find that Wegovy addresses weight while the topiramate need is reassessed. That is a clinical judgement, not one to make unilaterally.

For anyone wondering about the practical side of stopping Wegovy once started, the page on stopping Wegovy covers what to expect. Cost context for Wegovy as a private prescription is available on the Wegovy pricing page for those weighing up their options.

How does a prescriber at a service like nume handle this?

At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician, not a decision tree. The free online questionnaire asks for your current medicines list precisely because interactions like the topiramate-semaglutide overlap are exactly the kind of thing that changes the clinical picture. If you list topiramate, the prescriber reviews the reason, the dose and whether the combination is appropriate before any prescription is issued.

If you are approved, your treatment arrives via DPD the next working day in plain, unbranded packaging, the pen itself is a pre-filled injector, and tracking comes straight to your phone. Everything is included in one price: consultation, prescription, delivery and access to aftercare seven days a week. No separate fees, no auto-renewal. Our clinical team is available to answer follow-up questions after you start.

If the combination raises concerns your prescriber cannot resolve at the initial stage, they will say so clearly. That is part of what same-day clinical review means in practice. Explore Wegovy treatment at nume or read more about how Wegovy comes in a brown pen device before deciding what to ask in your consultation, alongside our weight-loss treatment options.